U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H25N5O8S2
Molecular Weight 539.582
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEZLOCILLIN

SMILES

[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C4=CC=CC=C4)C(O)=O

InChI

InChIKey=YPBATNHYBCGSSN-VWPFQQQWSA-N
InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1

HIDE SMILES / InChI

Description

Bayer developed MEZLOCILLIN (previously known as BAYPEN); it is a semisynthetic ampicillin-derived penicillin. Mezlocillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The bactericidal activity of mezlocillin results from the inhibition of cell wall synthesis and is mediated through mezlocillin binding to penicillin binding proteins (PBPs). Mezlocillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases and cephalosporinases and extended spectrum beta-lactamases. Mezlocillin was poorly absorbed orally and was given either intramuscularly or intravenously. This drug was discontinued in the U.S.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MEZLIN

Cmax

ValueDoseCo-administeredAnalytePopulation
216.6 mg/L
4 g single, intravenous
MEZLOCILLIN serum
Homo sapiens
317 mg/L
5 g single, intravenous
MEZLOCILLIN serum
Homo sapiens
138.84 mg/L
3 g single, intravenous
MEZLOCILLIN serum
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
275 mg × h/L
4 g single, intravenous
MEZLOCILLIN serum
Homo sapiens
403 mg × h/L
5 g single, intravenous
MEZLOCILLIN serum
Homo sapiens
415.2 mg × h/L
3 g single, intravenous
MEZLOCILLIN serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.32 h
4 g single, intravenous
MEZLOCILLIN serum
Homo sapiens
1.13 h
5 g single, intravenous
MEZLOCILLIN serum
Homo sapiens
2.1 h
3 g single, intravenous
MEZLOCILLIN serum
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Other
In Vitro Use Guide
Unknown